US2013296365A1PendingUtilityA1

Quinoline derivative-containing pharmaceutical composition

55
Assignee: EISAI R&D MAN CO LTDPriority: Aug 19, 2009Filed: Jun 21, 2013Published: Nov 7, 2013
Est. expiryAug 19, 2029(~3.1 yrs left)· nominal 20-yr term from priority
Inventors:Masashi Bando
A61P 35/00A61P 35/04A61P 43/00C07D 215/48A61K 31/47A61K 9/1652A61K 9/485A61K 47/02A61K 9/4866A61K 9/1611A61K 47/36
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof, and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: wherein, R 1 is a hydrogen atom, a C 1-6 alkyl group or a C 3-8 cycloalkyl group; and R 2 is a hydrogen atom or a methoxy group.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled) 
     
     
         13 . A pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate and an alkaline earth metal carbonate. 
     
     
         14 . The pharmaceutical composition according to  claim 13 , further comprising a disintegrating agent. 
     
     
         15 . The pharmaceutical composition according to  claim 13 , wherein the alkaline earth metal carbonate is calcium carbonate. 
     
     
         16 . The pharmaceutical composition according to  claim 15 , further comprising a disintegrating agent. 
     
     
         17 . The pharmaceutical composition according to  claim 13 , wherein the alkaline earth metal carbonate is magnesium carbonate. 
     
     
         18 . The pharmaceutical composition according to  claim 17 , further comprising a disintegrating agent. 
     
     
         19 . The pharmaceutical composition according to  claim 14 , wherein the disintegrating agent is at least one agent selected from carmellose sodium, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose and crospovidone. 
     
     
         20 . The pharmaceutical composition according to  claim 13 , wherein said pharmaceutical composition is in a capsule dosage form. 
     
     
         21 . The pharmaceutical composition according to  claim 15 , wherein said pharmaceutical composition is in a capsule dosage form. 
     
     
         22 . The pharmaceutical composition according to  claim 17 , wherein said pharmaceutical composition is in a capsule dosage form. 
     
     
         23 . A pharmaceutical composition comprising:
 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate; and   means for achieving dissolution of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.   
     
     
         24 . The pharmaceutical composition according to  claim 23 , wherein said pharmaceutical composition is in a capsule dosage form. 
     
     
         25 . The pharmaceutical composition according to  claim 23 , wherein said pharmaceutical composition is in a tablet dosage form. 
     
     
         26 . A pharmaceutical composition comprising:
 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate; and   means for achieving dissolution of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate at a dissolution rate that is higher than the dissolution rate of a composition identical to said pharmaceutical composition except lacking said means.   
     
     
         27 . The pharmaceutical composition according to  claim 26 , wherein said pharmaceutical composition is in a capsule dosage form. 
     
     
         28 . The pharmaceutical composition according to  claim 26 , wherein said pharmaceutical composition is in a tablet dosage form.

Join the waitlist — get patent alerts

Track US2013296365A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.